Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations

Kezar Life Sciences, Inc. (KZR)

10.37   0.37 (3.7%) 08-08 00:10
Open: 9.81 Pre. Close: 10
High: 10.47 Low: 9.45
Volume: 2,049,021 Market Cap: 627(M)
Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is KZR-616, a selective immunoproteasome inhibitor that is in Phase 2 clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; and Phase 1b clinical trials in systemic lupus erythematosus and lupus nephritis. Its preclinical products include KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of KZR-261; and KZR-TBD for the treatment of oncology and immunology. The company was incorporated in 2015 and is based in South San Francisco, California.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 10.47 - 10.51 10.51 - 10.54
Low: 9.35 - 9.4 9.4 - 9.44
Close: 10.3 - 10.36 10.36 - 10.42

Technical analysis

as of: 2022-08-05 4:23:27 PM
Stoxline posted a BUY today, upgraded from lower rating. Upward movement to be expected.
Target: Six months: 12.46     One year: 14.55
Support: Support1: 9.44    Support2: 8.68
Resistance: Resistance1: 10.67    Resistance2: 12.46
Pivot: 9.92
Moving Average: MA(5): 9.86     MA(20): 9.98
MA(100): 9.85     MA(250): 10.79
MACD: MACD(12,26): 0.4     Signal(9): 0.5
Stochastic oscillator: %K(14,3): 57.7     %D(3): 41.7
RSI: RSI(14): 63.8
52-week: High: 18.54  Low: 4.3
Average Vol(K): 3-Month: 2,380 (K)  10-Days: 812 (K)

Price, moving averages and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.
[ KZR ] has closed below upper band by 12.7%. Bollinger Bands are 73.1% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 12 bars. This is a sign that the market may be about to initiate a new trend.

Headline News

Wed, 03 Aug 2022
Victory Capital Management Inc. Buys 1396503 Shares of Kezar Life Sciences, Inc. (NASDAQ:KZR) - Defense World

Wed, 27 Jul 2022
Kezar Life Sciences: Regulatory Tailwinds Reverse Downside Case (NASDAQ:KZR) - Seeking Alpha

Wed, 20 Jul 2022
Zurcher Kantonalbank Zurich Cantonalbank Has $31000 Stock Position in Kezar Life Sciences, Inc. (NASDAQ:KZR) - Defense World

Tue, 19 Jul 2022
Kalamazoo Resources makes inroads at gold and lithium projects during June quarter - Small Caps

Mon, 11 Jul 2022
Kezar Life Sciences Appoints Nick Mordwinkin as Chief Business Officer and Reports Updated Cash Position - Business Wire

Tue, 28 Jun 2022
Kezar Life Sciences (KZR) Stock Soars on Lupus Trial Results - InvestorPlace

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Neutral
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Neutral
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 53 (M)
Shares Float 40 (M)
% Held by Insiders 23.6 (%)
% Held by Institutions 70.3 (%)
Shares Short 4,220 (K)
Shares Short P.Month 3,980 (K)

Stock Financials

EPS -1
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 2.46
Profit Margin (%) 0
Operating Margin (%) 0
Return on Assets (ttm) -18.5
Return on Equity (ttm) -32.4
Qtrly Rev. Growth 0
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -1
Qtrly Earnings Growth 0
Operating Cash Flow -42 (M)
Levered Free Cash Flow -23 (M)

Stock Valuations

PE Ratio -10.37
PEG Ratio 0
Price to Book value 4.21
Price to Sales 0
Price to Cash Flow -13

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
7 Binary Options
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.